<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H0138B02301BA4CF69A1F1F0385723105" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6749 IH: Menopause Research and Equity Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-12-13</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6749</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231213">December 13, 2023</action-date><action-desc><sponsor name-id="C001067">Ms. Clarke of New York</sponsor> (for herself, <cosponsor name-id="L000589">Mrs. Lesko</cosponsor>, <cosponsor name-id="B001303">Ms. Blunt Rochester</cosponsor>, <cosponsor name-id="H001085">Ms. Houlahan</cosponsor>, <cosponsor name-id="R000579">Mr. Ryan</cosponsor>, <cosponsor name-id="W000826">Ms. Wild</cosponsor>, <cosponsor name-id="L000551">Ms. Lee of California</cosponsor>, <cosponsor name-id="C001039">Mrs. Cammack</cosponsor>, <cosponsor name-id="V000081">Ms. Vel&#225;zquez</cosponsor>, <cosponsor name-id="P000599">Mr. Posey</cosponsor>, <cosponsor name-id="S001185">Ms. Sewell</cosponsor>, <cosponsor name-id="G000551">Mr. Grijalva</cosponsor>, <cosponsor name-id="T000481">Ms. Tlaib</cosponsor>, <cosponsor name-id="W000788">Ms. Williams of Georgia</cosponsor>, <cosponsor name-id="R000617">Mrs. Ramirez</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="N000002">Mr. Nadler</cosponsor>, <cosponsor name-id="M001160">Ms. Moore of Wisconsin</cosponsor>, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, <cosponsor name-id="P000618">Ms. Porter</cosponsor>, <cosponsor name-id="G000553">Mr. Green of Texas</cosponsor>, <cosponsor name-id="C001130">Ms. Crockett</cosponsor>, <cosponsor name-id="A000376">Mr. Allred</cosponsor>, <cosponsor name-id="C001127">Mrs. Cherfilus-McCormick</cosponsor>, <cosponsor name-id="K000385">Ms. Kelly of Illinois</cosponsor>, <cosponsor name-id="J000309">Mr. Jackson of Illinois</cosponsor>, <cosponsor name-id="L000599">Mr. Lawler</cosponsor>, <cosponsor name-id="W000822">Mrs. Watson Coleman</cosponsor>, <cosponsor name-id="B001300">Ms. Barrag&#225;n</cosponsor>, <cosponsor name-id="C001134">Ms. Caraveo</cosponsor>, <cosponsor name-id="G000586">Mr. Garc&#237;a of Illinois</cosponsor>, <cosponsor name-id="T000483">Mr. Trone</cosponsor>, <cosponsor name-id="V000130">Mr. Vargas</cosponsor>, <cosponsor name-id="B001281">Mrs. Beatty</cosponsor>, <cosponsor name-id="F000468">Mrs. Fletcher</cosponsor>, <cosponsor name-id="F000466">Mr. Fitzpatrick</cosponsor>, <cosponsor name-id="K000382">Ms. Kuster</cosponsor>, <cosponsor name-id="A000370">Ms. Adams</cosponsor>, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, and <cosponsor name-id="T000472">Mr. Takano</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Director of the National Institutes of Health to evaluate the results and status of completed and ongoing research related to menopause, perimenopause, or mid-life women&#8217;s health, to conduct and support additional such research, and for other purposes.</official-title></form><legis-body id="H3103A0B06EED498C82F71DAE1EA0FD0F" style="OLC"> 
<section id="H5840A55E5AF54C659C5C60848398B40C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Menopause Research and Equity Act of 2023</short-title></quote>.</text></section> <section id="H474649A7938F4D56A4484E0B96A939A7"><enum>2.</enum><header>Evaluation of completed and ongoing research related to menopause, perimenopause, or mid-life women’s health</header> <subsection id="HCA1AC840472140FFA86C7783E6ED18B4"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Director of the National Institutes of Health shall—</text> 
<paragraph id="H16008AD3D2984CDD9BDB11A39B9B5042"><enum>(1)</enum><text>conduct an evaluation of—</text> <subparagraph id="H394120FDEDC740C69BCD7FC977647272"><enum>(A)</enum><text display-inline="yes-display-inline">the results of research related to menopause, perimenopause, or mid-life women’s health that is complete;</text></subparagraph> 
<subparagraph id="HC241FAC9D8F94E31AD3C2AC3A1227E04"><enum>(B)</enum><text display-inline="yes-display-inline">the status of such research that is ongoing; and</text></subparagraph> <subparagraph id="H53BDCA89B1D24C4A9E54D6429ABC965B"><enum>(C)</enum><text>any gaps in knowledge and research on—</text> 
<clause id="H59E775E3629C4D54AAF52B794BB8CA16"><enum>(i)</enum><text>treatments for menopause-related symptoms; and</text></clause> <clause id="H6ABA452A243F41F9BDFB69C50D926984"><enum>(ii)</enum><text display-inline="yes-display-inline">the safety and effectiveness of treatments for menopause-related symptoms; and</text></clause></subparagraph></paragraph> 
<paragraph id="HC97C7B21688E442E96FE5D90B12268ED"><enum>(2)</enum><text display-inline="yes-display-inline">as part of such evaluation, identify the total amount of funding allocated by the National Institutes of Health for the conduct or support of research related to menopause, perimenopause, or mid-life women’s health over the preceding 5 fiscal years.</text></paragraph></subsection> <subsection id="H0AE20A2C6DA541F78DBBB9944B332029"><enum>(b)</enum><header>Report; strategic plan</header><text>Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall submit to the Congress—</text> 
<paragraph id="HC8B2C43243EA46779E32F5C80042EA9F"><enum>(1)</enum><text>a plan to perform the evaluation under subsection (a); and</text></paragraph> <paragraph id="H4C9D127A6A0C4B9BBDF1F42E4F531A3D"><enum>(2)</enum><text>a plan to develop a strategy, based on such evaluation, that will—</text> 
<subparagraph id="HF764CE00C501429CB39C131E54F48A93"><enum>(A)</enum><text>be designed and implemented by the Director in cooperation with a multidisciplinary group of health professionals including gynecologists, oncologists, endocrinologists, cardiologists, and neuroscientists;</text></subparagraph> <subparagraph id="H11EC9B9DA69441E0A1B39BEFDF75F16D"><enum>(B)</enum><text>include strategies to resolve the gaps in knowledge and research identified in the report; and</text></subparagraph> 
<subparagraph id="H17816D0DA8594270A64BE48E68CBF56A"><enum>(C)</enum><text>identify topics in need of further research relating to potential treatments for menopause-related symptoms.</text></subparagraph></paragraph></subsection></section> <section id="H21337C08F7C049E4B7D6C1AA7C3A23A1"><enum>3.</enum><header>Additional research related to menopause, perimenopause, or mid-life women’s health</header> <subsection id="H2F695015D8AC4349A2FD68CC024D5732"><enum>(a)</enum><header>Additional research</header> <paragraph id="H0B6D098954234F6EA2EDD75E96073AE0"><enum>(1)</enum><header>In general</header><text>The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct or support research related to menopause, perimenopause, or mid-life women’s health.</text></paragraph> 
<paragraph id="H155DDC8A25CD40969F495738FA21B3B9"><enum>(2)</enum><header>Required elements</header><text display-inline="yes-display-inline">The research required by paragraph (1) shall include—</text> <subparagraph id="H27FB0A3BDBDC48A3A93DDB54D3A54706"><enum>(A)</enum><text>research concerning causes, symptoms, and treatments for menopause, perimenopause, and other related mid-life women’s health issues; and</text></subparagraph> 
<subparagraph id="H71961B9CDE92455EAD17DE46133FA956"><enum>(B)</enum><text>a multidisciplinary study of the effects of hormonal treatment for menopausal symptoms.</text></subparagraph></paragraph></subsection></section> <section id="H89FEDC78B51542399CD3ACA8278C5C99"><enum>4.</enum><header>No additional funds authorized to be appropriated</header><text display-inline="no-display-inline">No additional funds are authorized to be appropriated to carry out this section, and this section shall be carried out using amounts otherwise available for such purpose.</text></section> 
</legis-body></bill>

